Eloxx: Funding, Investors & Team (Oct 2026)
Eloxx Pharmaceuticals, an Israeli company, was founded in 2013 by Dr. Silvia Noiman and Dr. Shmuel Tuvia. As a biopharmaceutical company, Eloxx Pharmaceuticals focuses on discovering, developing, and commercializing compounds to treat genetic diseases caused by nonsense mutations. These diseases include cystic fibrosis, Duchene Muscular Dystrophy, Usher syndrome, Ataxia-telangiectasia, Beta thalassemia, Tay-Sachs Hurler syndrome, and several others. The company's expertise allows them to quickly progress from identifying potential drugs to developing clinical candidates. Eloxx Pharmaceuticals aims to build a robust pipeline of molecules that specifically target nonsense genetic diseases. By inducing ribosomal readthrough, these molecules overcome nonsense mutations and enable the production of fully functional proteins. This approach has significant therapeutic potential for the treatment of various genetic diseases.
Eloxx has raised $114M across 4 funding rounds on record, the most recent an undisclosed round of $66.0M announced in Jun 2026.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Eloxx Company Profile and Key Stats
Latest funding round on record: Jun 2026.
Eloxx Funding Rounds
Eloxx raised $30.0M in a Post-IPO Debt announced in Oct 2021.
5 months later, a Grant of $15.9M was announced in Mar 2022.
1.5 years later, an undisclosed round of $2.0M was announced in Sep 2023.
2.8 years later, an undisclosed round of $66.0M was announced in Jun 2026.
Eloxx Founders and Leadership Team
Contact details for the Eloxx team: 1 of 4 have an email address on file.
Start 14-day free trial →Eloxx Funding Compared to Other Biotechnology Startups
Eloxx's latest round of $66.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Eloxx in Biotechnology and Waltham
Companies Similar to Eloxx
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Eloxx Funding FAQs
What does Eloxx do?
Eloxx Pharmaceuticals, an Israeli company, was founded in 2013 by Dr. Silvia Noiman and Dr. Shmuel Tuvia. As a biopharmaceutical company, Eloxx Pharmaceuticals focuses on discovering, developing, and commercializing compounds to treat genetic diseases caused by nonsense mutations. These diseases include cystic fibrosis, Duchene Muscular Dystrophy, Usher syndrome, Ataxia-telangiectasia, Beta thalassemia, Tay-Sachs Hurler syndrome, and several others. The company's expertise allows them to quickly progress from identifying potential drugs to developing clinical candidates. Eloxx Pharmaceuticals aims to build a robust pipeline of molecules that specifically target nonsense genetic diseases. By inducing ribosomal readthrough, these molecules overcome nonsense mutations and enable the production of fully functional proteins. This approach has significant therapeutic potential for the treatment of various genetic diseases.
How much funding has Eloxx raised?
Eloxx has raised $114M across 4 rounds on record. The most recent is an undisclosed round of $66.0M announced in Jun 2026.
When did Eloxx last raise funding?
Eloxx's most recent funding round on record is an undisclosed round of $66.0M, announced in Jun 2026.
Who founded Eloxx?
FundedIQ lists Bob Ward (Founder), Silvia Noiman (Founder) at Eloxx.
Who is the CEO of Eloxx?
Robert Ward is listed as CEO at Eloxx.
Where is Eloxx headquartered?
Eloxx is based in Waltham, Massachusetts, United States.
How many employees does Eloxx have?
Eloxx is in the 11-50 employee band.
How does Eloxx's funding compare to other Biotechnology startups?
Eloxx's latest round of $66.0M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Eloxx Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Eloxx is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.